97 results
Page 2 of 5
8-K
EX-99.1
zk9rnb hwya
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
zx3cu0cbz9v ua3hpj
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
PRE 14A
tp5djqctvu9vwqua01z
17 Apr 23
Preliminary proxy
5:04pm
8-K
EX-99.1
2ekgk nc712
3 Apr 23
Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares
5:17pm
8-K
EX-99.1
0fpsdf3s61d1o
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
8-K
ggdw 85qrhz
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
424B5
034o29ej76y3
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
ziien4dp 94f
29 Mar 23
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
a9vogxaeq9w4k
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
93icf78 d0dnd
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
53r4khg
27 Apr 22
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
375g12bc729hg
9 Feb 22
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
4:15pm